EP0942653A1 - Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact - Google Patents

Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact

Info

Publication number
EP0942653A1
EP0942653A1 EP97948172A EP97948172A EP0942653A1 EP 0942653 A1 EP0942653 A1 EP 0942653A1 EP 97948172 A EP97948172 A EP 97948172A EP 97948172 A EP97948172 A EP 97948172A EP 0942653 A1 EP0942653 A1 EP 0942653A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
solution
group
lens
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97948172A
Other languages
German (de)
English (en)
Inventor
Susan P. Spooner
David J. Heiler
Lisa C. Simpson
David A. Marsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of EP0942653A1 publication Critical patent/EP0942653A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/141—Biguanides, e.g. chlorhexidine
    • A61L12/142—Polymeric biguanides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof

Definitions

  • This invention relates to new and improved solutions for the treatment of contact lenses and to methods for treating contact lenses with such solutions.
  • the present invention is directed to disinfecting solutions comprising certain bis(biguanides) and to their use in improved regimens for treating contact lenses.
  • contact lenses in wide use fall into three categories: (1) hard lenses formed from materials prepared by polymerization of acrylic esters, such as polymethyl methacrylate (PMMA), (2) rigid gas permeable (RGP) lenses formed from silicone acrylates and fluorosilicone methacrylates, and (3) gel, hydrogel or soft type lenses made of polymerized hydrophilic or hydrophobic monomers, such as 2-hydroxyethyl methacrylate (HEMA).
  • PMMA polymethyl methacrylate
  • RGP rigid gas permeable lenses formed from silicone acrylates and fluorosilicone methacrylates
  • gel, hydrogel or soft type lenses made of polymerized hydrophilic or hydrophobic monomers, such as 2-hydroxyethyl methacrylate (HEMA).
  • HEMA 2-hydroxyethyl methacrylate
  • the hard acrylic type contact lenses are characterized by low water vapor diffusion constants, resistance to the effects of light, oxygen and hydrolysis and absorb only minor amounts of aqueous fluids. Because of the durability of hard contact lenses, coupled
  • soft type contact lenses and certain of the newer rigid gas permeable contact lenses have a tendency to bind and concentrate significantly more fluids, environmental pollutants, water impurities, as well as antimicrobial agents and other active ingredients commonly found in lens care solutions.
  • the low levels of the ingredients in lens care solutions do not lead to eye tissue irritation when used properly.
  • some disinfecting agents and preservatives tend to build up on lens surfaces and may become concentrated to potentially hazardous levels, such that when released could cause corneal inflammation and other eye tissue irritation.
  • the antimicrobial activity of the chlorhexidine may be diminished when used with certain amphoteric surfactants. Furthermore, it was reported that if not used in proper ratio, the surfactant and disinfectant will precipitate unless a non-ionic type surfactant is also employed.
  • U.S. patent 4,361,548 discloses a contact lens disinfectant and preservative containing dilute aqueous solutions of a polymer; namely, polydimethyldiallylammonium chloride (DMDAAC) having molecular weights ranging from about 10,000 to 1,000,000. Amounts of DMDAAC homopolymer as low as 0.00001 percent by weight may be employed when an enhancer, such as thimerosal, sorbic acid or phenylmercuric salt is used therewith. Although lens binding and concomitant eye tissue irritation with DMDAAC were reduced, it was found in some users to be above desirable clinical levels.
  • DMDAAC polydimethyldiallylammonium chloride
  • British Patent 1,432,345 discloses contact lens disinfecting compositions containing a polymeric biguanide and a mixed phosphate buffer.
  • the products embraced by this patent have not found acceptance by the consumer.
  • Corneal staining is an indication of patient acceptability and compositions as disclosed by this patent have staining values of 17% or more present, far above that which is desirable for patient acceptability.
  • U.S. Patent 4,758,595 to Ogunbiyi et al. disclosed that a contact-lens solution containing a polyaminopropyl biguanide (PAPB) has enhanced efficacy when combined with a borate buffer.
  • PAPB polyaminopropyl biguanide
  • Such solutions are compatible with both non-soft and soft-type lenses, and are adaptable for use with virtually any of the commonly known disinfecting techniques, including "cold" soaking under ambient temperature conditions, as well as with high temperature disinfecting methods.
  • These disinfecting and preservative solutions are especially noteworthy for their broad spectrum of bactericidal and fungicidal activity at low concentrations coupled with very low toxicity when used with soft-type contact lenses.
  • Ogunbiyi et al. stated that biguanide polymers in the higher molecular weight ranges usually demonstrate lower toxicity levels than corresponding lower molecular weight materials.
  • compositions containing PAPB and borate, or other non-phosphate buffers have been commercialized in various products, but at levels of about 1 ppm or less for use with soft contact lenses. It is generally desirable to provide the lowest level of a bactericide possible, while maintaining the desirable level of disinfection efficacy, in order to provide a generous margin for safety and comfort.
  • Some of the most popular products for disinfecting lenses are multipurpose solutions that can be used to clean, disinfect and wet contact lenses, followed by direct insertion (placement on the eye) without rinsing. Obviously, the ability to use a single solution for contact-lens care is an advantage. Such a solution, however, must be particularly gentle to the eye, since, as indicated above, some of the solution will be on the lens when inserted and will come into contact with the eye.
  • lens wearers typically need to digitally or manually rub the contact lenses (typically between a finger and palm or between fingers) during daily cleaning and/or disinfecting of contact lenses.
  • the necessity for frequent "rubbing" of contact lenses adds to the time and effort involved in the daily care of contact lenses.
  • Some wearers may be negligent in the proper "rubbing" regimen, which may result in contact-lens discomfort and other problems.
  • Sometimes rubbing, if performed too rigorously, which is particularly apt to occur with beginning lens wearers, may damage the lenses. This can be very problematic or inconvenient when a replacement lens is not immediately available.
  • a contact lens solution that does not require rubbing would generally require a more efficacious or stronger disinfectant than a solution that does not require rubbing.
  • the stronger the bactericidal effect of a solution however, the more likely that it may exhibit toxic effects or adversely effect lens-wearer comfort.
  • many very efficacious bactericides used in other contexts, such as mouthwashes, cosmetics, or shampoos, while being sufficiently safe for use in such products would be too toxic for ophthalmic use, especially for use with soft lenses because of the above-mentioned tendency of soft lenses to bind chemicals.
  • the concentrations of certain bactericides may need to be within lower limits in solutions for use with soft contact lenses than in other products or in solutions for other types of lenses, especially when such solutions are for use in the eye. It would be desirable to obtain a contact-lens solution that would simultaneously provide both (1) an increased level of antibacterial activity, and (2) a low order of toxicity to eye tissue, such that the solution can be used to treat contact lenses without rinsing, despite any tendency of a disinfectant to bind onto lens surfaces.
  • the present invention is directed to an ophthalmically safe disinfecting solution for contact lenses comprising about 2.0 to about 8.0 ppm of a bis(biguanide) in the form of a dihydrochloride salt, or a corresponding concentration of the same bis(biguanide) in the form of the free base or a different water-soluble salt, which bis(biguanide) has the following general formula:
  • R 1 and R 4 are independently selected (i.e., the same or different) from the group consisting of branched or unbranched alkyl having 4-12 carbon atoms, alkoxyalkyl or alkylsulfide radical having 4-12 carbon atoms, or cycloalkyl or cycloalkyl-alkyl radical having 5-12 carbon atoms;
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl having 1-12 carbon atoms, alkoxyalkyl having 1-12 carbon atoms, or cycloalkyl or cycloalkyl-alkyl having 5-12 carbon atoms;
  • R 6 and R 7 are independently selected from the group consisting of hydrogen and alkyl radical having 1-6 carbon atoms, and
  • a in the above formula is a divalent group having 4-16 carbon atoms and is selected from the group consisting of an alkylene, alkyloxyalkyl, and alkylsufide radical, wherein the aforesaid
  • the solutions of the present invention also comprise an effective amount of one or more buffering agents, preferably in the amount of from about 0.01 to 5% by weight of the composition (solution), an effective amount of one or more surfactants, preferably in an amount of about 0.01% to 5% by weight, and water in an amount of at least about 90% by weight.
  • the surfactant is a neutral or nonionic surfactant.
  • the invention is also directed to a method of cleaning and/or disinfecting a contact lens comprising soaking the lens for a given period of time in an aqueous solution comprising a microbiocidally effective amount, within the range from about 2.0 to about 8.0 ppm, preferably 2.0 to 6.0 ppm, of a bis(biguanide) of Formula (I) in the form of the hydrochloride salt (or a corresponding concentration or molar amount of the same bis(biguanide) in the form of the free base or a salt other than the hydrochloride), an effective amount of a buffering agent, and an effective amount of a surfactant, and subsequently directly placing the treated lens on an eye of the wearer.
  • the contact lens does not require rubbing with the solution to achieve the necessary disinfection.
  • 0.1 to 4.0 ppm of a bis(biguanide) of Formula (I) has been shown to provide synergistic efficacy in combination with a polymeric biguanide in the amount of 0.1 to 3.0 ppm.
  • the present invention is directed to a composition, in the form of an aqueous solution containing a compound of Formula (I) above, and a method of using the solution for disinfecting and/or preserving contact lenses, especially soft contact lenses.
  • the disinfecting solutions of the present invention are effective at low concentrations against a wide spectrum of microorganisms, including but not limited to Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Candida albicans, and Fusarium solani.
  • a disinfecting solution is generally defined as a contact- lens care product containing one or more active ingredients (for example, anti-microbial agents and/or preservatives) in sufficient concentrations to destroy harmful microorganisms on the surface of a contact lens within the recommended minimum soaking time.
  • active ingredients for example, anti-microbial agents and/or preservatives
  • the recommended minimum soaking time is included in the package instructions for use of the disinfecting solution.
  • the present solution, in combination with its container or bottle and packaging, including instructions for use in accordance with a specified regimen, may be considered a novel and improved kit, package, or system for the care of contact lenses.
  • soft lens is meant a lens having a proportion of hydrophilic repeat units such that the water content of the lens during use is at least 20% by weight.
  • soft contact lens generally refers to those contact lenses which readily flex under small amounts of force.
  • soft contact lenses are formulated from polymers having a certain proportion of repeat units derived from hydroxyethyl methacrylate and/or other hydrophilic monomers, typically crosslinked with a crosslinking agent.
  • disinfecting solution is meant a solution containing one or more microbiocidal compounds, that is effective for reducing or substantially eliminating the presence of an array of microorganisms present on a contact lens, which can be tested by challenging the solution, or a contact lens that has been immersed in the solution, with specified inoculums of such microorganisms.
  • disinfecting solution does not exclude the possibility that the solution may also be useful as a preserving solution, or that the disinfecting solution may also be useful for other purposes such as daily cleaning, rinsing and storage of contact lenses, depending on the particular formulation.
  • a solution that is useful for cleaning, chemical disinfection, storing, and rinsing a contact lens is referred to herein as a "multi-purpose solution.”
  • Such solutions may be part of a “multi-purpose solution system” or “multi-purpose solution package.”
  • the procedure for using a multi-purpose solution, system or package is referred to as a "multifunctional disinfection regimen.”
  • Multi-purpose solutions do not exclude the possibility that some wearers, for example, wearers particularly sensitive to chemical disinfectants or other chemical agents, may prefer to rinse or wet a contact lens with another solution, for example, a sterile saline solution prior to insertion of the lens.
  • multi-purpose solution also does not exclude the possibility of periodic cleaners not used on a daily basis or supplemental cleaners for removing proteins, for example enzyme cleaners, which are typically used on a weekly basis.
  • cleaning is meant that the solution contains one or more cleaning agents in sufficient concentrations to loosen and remove loosely held lens deposits and other contaminants on the surface of a contact lens, especially if used in conjunction with digital manipulation (for example, manual rubbing of the lens with a solution) or with an accessory device that agitates the solution in contact with the lens, for example, a mechanical cleaning aid.
  • the critical micelle concentration of a surfactant-containing solution is one way to evaluate its cleaning effectiveness.
  • an effective multi-purpose solution refers to a solution useful for daily chemical disinfection, storing, and rinsing a contact lens, which solution does not require cleaning that involves rubbing, but which solution still obviates the need for any other solution for daily cleaning, that is, no other solution must be used in conjunction or combination with the solution on a daily basis.
  • Such solutions may comprise a surfactant or other agent for loosening or preventing lens deposits to some extent.
  • Such a solution does not require digital rubbing or similar manual or mechanical means that provide a rubbing action (a means for providing pressure and friction along the surface of the lens) to remove deposits from a lens.
  • a no-rub regimen may be especially applicable to a frequent replacement lens, a lens which is recommended for replacement after a limited number of days in the eye of the wearer, for example, after being worn about 30 days or less, preferably after being worn about 14 days or less.
  • ophthalmically safe with respect to a contact-lens solution is meant that a contact lens treated with the solution is safe for direct placement on the eye without rinsing, that is, the solution is safe and comfortable for daily contact with the eye via a contact lens that has been wetted with the solution.
  • An ophthalmically safe solution has a tonicity and pH that is compatible with the eye and comprises materials, and amounts thereof, that are non-cytotoxic according to ISO standards and U.S. FDA (Food & Drug Administration) regulations.
  • the bis(biguanide) germicides employed in the present solutions include compounds, and their water-soluble salts, having following formula:
  • R 1 and R 4 are independently selected (i.e., the same or different) from the group consisting of branched or unbranched alkyl having 4-12, preferably 6-10, carbon atoms, alkoxyalkyl (i.e., ether) or alkylsulfide (thioether or dialkylsulfide) radical having 4-12, preferably 6-10, carbon atoms, or cycloalkyl or cycloalkyl-alkyl radical having 5-12, preferably 7-10, carbon atoms;
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl having 1-12, preferably 1-6, carbon atoms, alkoxyalkyl having 1-12, preferably 1-6, carbon atoms, or cycloalkyl or cycloalkyl-alkyl having 5-12, preferably 6-10, carbon atoms;
  • R 6 and R 7 are independently selected from the group consisting of hydrogen and alkyl radical having 4-12, preferably 6-10, carbon atom
  • cycloalkyl either in cycloalkyl or cycloalkyl-alkyl, is meant unsubstituted or substituted cycloalkyl, where the substituents are one or more alkyl, alkoxy (-OR) , or alkylthio (-SR) groups having 1-6 carbon atoms.
  • the biguanides of Formula (I) are suitably used in the total amount (with respect to the weight of the hydrochloride salt, often containing two hydrochlorides as in alexidine) of 2.0 to 8.0 ppm, preferably 2.5 to 6.0 ppm based on the total aqueous solution. More preferably, the bis(biguanides) are used in the amount of 3.0 to 5.0, most preferably 3.5 to 4.5 ppm, with respect to the hydrochloride salt, or a corresponding molar amount of another salt or its free base.
  • the above-indicated ppm ranges must be adjusted to obtain the corresponding ppm ranges such that the ranges are the same on a molar basis as for the hydrochloride salt of the bis(biguanide).
  • concentration of the bis(biguanide) in solution is directly related to its bactericidal efficacy.
  • the corresponding weight of an equal molar amount or equal concentration of a different salt form of a bis(biguanide) can be readily calculated, for use determining a suitable amount of the ingredient.
  • ppm refers to "parts per million" and 1.0 ppm corresponds to 0.0001 percent by weight. It is based on the total weight of the composition or, in this case, the total weight of the aqueous disinfecting solution.
  • the amount of the bis(biguanide) or other components in a solution according to the present invention refers to the amount formulated and introduced into the solution at the time the solution is made. Over time (for example, over a storage period of 18 months), the assayed amount of a bis(biguanide) in solution may decrease somewhat.
  • the bis(biguanide) compounds have the following formula:
  • R 1 and R 4 are independently selected from the group consisting of branched or unbranched alkyl, alkoxyalkyl (i.e., ether) or alkylsulfide (thioether) radical, and n is 5 to 7.
  • R 1 and R 4 in Formulas (I) or (II) above may be, for example, an n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, octyl, 2-ethylhexyl, dodecyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radical.
  • 2-ethylhexyl (alexidine), 1,5-dimethylhexyl, 1-methylhexyl, 1,3- dimethylpentyl, 1,4-dimethylpentyl, cyclohexylmethyl, 2-norbornyl, propyloxyoctyl, and propyloxybutyl.
  • R 2 and R 3 in Formula (I) above may be, for example, a methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, octyl, 2- ethylhexyl, dodecyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radical.
  • R 2 and R 3 is an alkoxyalkyl radical, it may be, for example, a 2-methoxyethyl.
  • R 6 and R 7 in Formula (I) may be, for example, a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or neopentyl radical.
  • Preferred A groups in Formula (I) include hexamethylene and a divalent hexamethylene interrupted with a divalent radical derived from N,N'-(2-aminoethyl)-l,4- piperadine or the like in which each of the nitrogen atoms are connected to a polymethylene group having 1 to 4 carbon atoms.
  • the acid-addition salts of the invention may be derived from an inorganic or organic acid. In most circumstances it is preferable that the salts be derived from an acid which is readily water soluble and which affords an anion which is suitable for human usage, for example a pharmaceutically-acceptable anion.
  • acids are hydrochloric, hydrobromic, phosphoric, sulphuric, acetic, D-gluconic, 2-pyrrolidino-5- carboxylic, methanesulphonic, carbonic, lactic and glutamic acids.
  • the hydrochloride salt is preferred.
  • the bis(biguanides) of Formula (I) preferably have relatively hydrophobic end groups.
  • the Log P of the compounds is 5 to 10, preferably 6 to 8, wherein P is the partition coefficient of the free base, using the following equation, wherein ⁇ is the degree of ionization:
  • the compound is partitioned between a 0.05 M phosphate buffer (pH 11) saturated with octanol and octanol saturated with phosphate buffer after gentle shaking at room temperature (26 °C).
  • the volume ratio of these two phases and the amount of sample are chosen so that the absorbance of the sample from the buffered layer after partitioning has a value between 0.2 and 0.9, using a 1-cm cell and buffer solution as a blank.
  • Particularly preferred bis(biguanide) compounds of this invention are 2- (decylthiomethyl)-pentane-l,5-bis(5-isopropylbiguanide), 2-(decylthio-methyl)pentane- l,5-bis(5,5-diethylbiguanide), and hexane-l,6-bis(2-ethylhexylbiguanide), the latter also known as alexidine or l,l'-hexamethylenebis(5-(2-ethylhexyl)-biguanide) dihydrochloride.
  • bis(biguanides) include l,l '-hexamethylenebis(5-heptyl-biguanide) dihydrochloride, l,l '-hexamethylenebis(5-octyl-biguanide) dihydrochloride, and 1,1 '- hexamethylenebis(5-hexyl-biguanide) dihydrochloride.
  • the biguanide compounds of Formula (I) wherein R 6 and R 7 are each hydrogen may be made by reacting a bis-cyanoguanidine of the formula:
  • the reactants are heated together until the reaction is complete.
  • the reaction proceeds fastest at higher temperatures, but if thermal stability is a problem, the reaction should be carried out at lower temperature for a longer period.
  • the reactants are most conveniently melted together in the absence of a solvent, but if desired an inert solvent such as DMSO, 2-methoxyethanol, 2-ethoxyethanol, nitrobenzene, sulpholane, isopropanol, n-butanol, ethylene glycol dimethyl ether or water, or a mixture of such solvents, may be used.
  • the bis-cyanoguanidine of the Formula (VI) may be manufactured from known starting materials such as hexamethylenedinitrile which is reduced, for example, with hydrogen and Raney nickel or with borane in dimethyl sulphide to the corresponding diamine (VIII), and the diamine in the form of an acid-addition salt, conveniently the dihydrochloride, is reacted with sodium dicyanamide or other suitable salt to form the required starting material (VI), as depicted below.
  • known starting materials such as hexamethylenedinitrile which is reduced, for example, with hydrogen and Raney nickel or with borane in dimethyl sulphide to the corresponding diamine (VIII), and the diamine in the form of an acid-addition salt, conveniently the dihydrochloride, is reacted with sodium dicyanamide or other suitable salt to form the required starting material (VI), as depicted below.
  • M is a sodium, potassium, zinc or other suitable salt.
  • the sodium salt is commercially available.
  • the compounds of the present invention can also be made by reacting a diamine of the Formula (VIII) in the form of an acid addition salt, with a cyanoguanidine of the formula:
  • a suitable salt of the diamine is, for example, the dihydrochloride.
  • the reactants are heated together until the reaction is complete. The reaction proceeds fastest at higher temperature, but if thermal stability is a problem, the reaction should be carried out at lower temperature over a longer period. If a melt can be formed at those temperatures the reactants are conveniently melted together in the absence of a solvent. If not, or alternatively, the reactants are heated together in a suitable inert solvent, for example those mentioned above.
  • the acid-addition salts of the invention are obtained by conventional means.
  • cyanoguanidines of the Formulae (IX) and (X) wherein R 6 and R 7 are hydrogen may be obtained by reacting sodium dicyanamide with an appropriate amine R'R 2 NH or R 3 R 4 NH, in the form of an acid-addition salt, conveniently the dihydrochloride, in a suitable inert solvent.
  • cyanoguanidines of the Formulae (IX) and (X) wherein R 6 and R 7 are other than hydrogen which may be used as starting materials in the above process, may be obtained by reacting a dialkyl (cyanoimido)dithio-carbonate, for example dimethyl
  • the bis(biguanide) known as alexidine is produced from the following sequence of reactions.
  • Compound (XI) is hexamethylenediamine dihydrochloride (MW 189), Compound (XII) is sodium dicyanamide, Compound XIII is HMBD A, hexamethylene bis(cyanoguanido), Compound (XIV) is 2-ethyl-hexylamine hydrochloride (MW 165.7), and Compound (XV) is alexidine dihydrochloride a.k.a. [l,6-bis-(2-ethylhexylbiguanido]hexane dihydrochloride a.k.a. hexane-l,6-bis(2-ethylhexyl biguanide) dihydrochloride.
  • This compound has a molecular weight in g/mole (MW) of 581.7 and empirical formula C 2 6H 56 N ⁇ o-2HCl.
  • the Compound (XV) is commercially available from various sources, including Sigma Chemical Co. (St Louis, Missouri).
  • a compound of Formula (VII) may be made from hexenedinitrile by reaction with R 5 YH, where Y is an oxygen or sulfur atom as a strong base.
  • R 5 YH where Y is an oxygen or sulfur atom as a strong base.
  • R 2 and R 3 are H, can be readily obtained as N derivatives of 1,6- bis(biguanido)hexane.
  • the methods for synthesized compounds of the present invention are also disclosed in European Patent Application Publication No. 0 125 092 (published 14.11.84); Rose, F.L.
  • a second disinfectant/germicide can be employed as a solution preservative, but it may also function to potentiate, compliment or broaden the spectrum of microbiocidal activity of Formula (I).
  • Suitable complementary germicidal agents include, but are not limited to thimerosol, sorbic acid, alkyl triethanolamines, phenylmercuric salts, e.g. nitrate, borate, acetate, chloride and mixtures thereof.
  • Suitable salts are soluble in water at ambient temperature to the extent of at least 0.5 weight percent. These salts include the gluconate, isethionate, (2-hydroxyethanesulfonate), formate, acetate, glutamate, succinanate, monodiglycollate, methanesulfonate, lactate, isobutyrate and glucoheptonate. Further embodiments of potentiating or complementary disinfecting agents for use in the present invention also include certain quaternary ammonium compounds which possess a generally wide spectrum of bacteriocidal activity and wetting properties. Representative examples of the quaternary ammonium compounds are compositions comprised of balanced mixtures of n-alkyl dimethyl benzyl ammonium chlorides. Other examples include polymeric quaternary ammonium salts used in ophthalmic applications such as polyquaternium 1® (chemical registry number 75345-27-6) available from Onyx corporation.
  • the bis(biguanides) defined above may be used in combination with lesser amounts of other bis(biguanides), for example chlorhexidine.
  • Such compounds have been disclosed in greater detail in United Kingdom patent specification No. 705,838.
  • the bis(biguanides) of the present invention may be used in combination with one or more polymeric biguanides.
  • one embodiment of the present invention is directed to an ophthalmically safe disinfecting solution for contact lenses comprising: about 0.10 to about 4.0 ppm of a bis(biguanide), as defined herein, in combination with 0.10 to 3.0 ppm of a polymeric biguanide.
  • the bisbiguanide has Formula (II) provided above, wherein R 1 and R 4 are independently selected from the group consisting of branched or unbranched alkyl having 4-12, preferably 6-10, carbon atoms, alkoxyalkylor alkylsulfide radical having 4-12, preferably 6-10, carbon atoms, or cycloalkyl or cycloalkyl-alkyl radical having 5-12, preferably 7-10, carbon atoms; and n is 4 to 16, preferably 4 to 10.
  • the bis(biguanides) of Formula (I) are suitably used (with respect to the weight of the hydrochloride salt, often containing two hydrochlorides as in alexidine) in the amount of 0.1 to 4.0 ppm, preferably 1.0 to 3.0 ppm based on the total aqueous solution. More preferably, the bis(biguanides) are used in the amount of 1.5 to 2.5, most preferably about 2.0 ppm, with respect to the hydrochloride salt, or a corresponding molar amount of another salt or its free base.
  • the bis(biguanide) that is used in the present invention is in the form of the free base or a salt other than the hydrochloride, then the above-indicated ppm ranges must be adjusted to obtain the corresponding ppm ranges such that the ranges are the same on a molar basis as for the hydrochloride salt of the bis(biguanide).
  • 0.10 to 4.0 ppm of the bis(biguanides) of the present invention may be used in combination with one or more polymeric biguanides, and water-soluble salts thereof, having the following formula:
  • Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is on average at least 3, preferably on average 5 to 20, and X 1 and X 2 are independently selected from the groups -NH 2 and -NH - C - NH - CN.
  • water-soluble polymeric biguanides will have number average molecular weights of at least 1,000 and more preferably will have number average molecular weights from 1,000 to 50,000.
  • Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
  • the above-disclosed biguanides and methods of preparation are described in the literature. For example, U.S. patent 3,428,576 describes the preparation of polymeric biguanides from a diamine and salts thereof and a diamine salt of dicyanimide.
  • the polymeric biguanides in combination with the bisbiguanides of the present invention, are effective in concentrations as low as 0.00001 weight percent (0.1 ppm). It has also been found that the bactericidal activity of the solutions may be enhanced or the spectrum of activity broadened through the use of a combination of such polymeric biguanides with the compounds of Formula (I) above.
  • the effective amount of the polymeric biguanides (irrespective of the particular salt form or whether the free base is used ) may in total be as low as about 0.000010 weight percent (0.10 ppm) and up to about 0.00030 weight percent (3.0 ppm) in the present invention, whether in the form of a water-soluble salt or the free base.
  • the total amount of polymeric biguanide, in combination with the total amount of compounds of Formula (I) above is about 0.3 to 2.0 ppm, more preferably about 0.4 to 1.0, most preferably about 0.5 to 0.8 ppm.
  • the polymeric hexamethylene biguanides commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, DE) under the trademark CosmocilTM CQ.
  • Such polymers and water-soluble salts are referred to as PHMB or polyaminopropyl biguanide (PAPB).
  • polyhexamethylene biguanide is meant to encompass one or more biguanides have the following formula: X 1 — (CH 2 ) 3 - -(CH 2 ) 3 -NH-C-NH-C-NH— (CH 2 ) 3 - (CH 2 ) 3 -X 2 NH NH
  • the predominant compound falling within the above formula may have different X 1 and X 2 groups or the same groups, with lesser amounts of other compounds within the formula.
  • Such compounds are known and are disclosed in US Patent No. 4,758,595 and British Patent
  • the water-soluble salts are compounds where n has an average value of 2 to 15, most preferably 3 to 12.
  • the present solution comprises at least one surfactant.
  • Suitable surfactants can be either amphoteric, cationic, anionic, or nonionic which may be present (individually or in combination) in amounts up to 15 percent, preferably up to 5 percent by weight of the composition or solution.
  • Preferred surfactants are amphoteric or nonionic surfactants, which when used impart cleaning and conditioning properties.
  • the surfactant should be soluble in the lens care solution and non-irritating to eye tissues.
  • Many nonionic surfactants comprise one or more chains or polymeric components having oxyalkylene (- O-R-) repeats units wherein R has 2 to 6 carbon atoms.
  • Preferred non-ionic surfactants comprise block polymers of two or more different kinds of oxyalkylene repeat units, which ratio of different repeat units determined the HLB of the surfactant.
  • Satisfactory non-ionic surfactants include polyethylene glycol esters of fatty acids, e.g. coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of higher alkanes (Ci2-Ci8)-
  • Examples of the preferred class include polysorbate 20 (available under the trademark Tween® 20), polyoxyethylene (23) lauryl ether (Brij® 35), polyoxyethyene (40) stearate (Myrj® 52), polyoxyethylene (25) propylene glycol stearate (Atlas® G 2612).
  • One nonionic surfactant in particular consisting of a poly(oxypropylene)-poly(oxyethylene) adduct of ethylene diamine having a molecular weight from about 7,500 to about 27,000 wherein at least 40 weight percent of said adduct is poly(oxyethylene) has been found to be particularly advantageous for use in cleaning and conditioning both soft and hard contact lenses when used in amounts from about 0.01 to about 15 weight percent.
  • CTFA Cosmetic Ingredient Dictionary's adopted name for this group of surfactants is poloxamine.
  • Such surfactants are available from BASF Wyandotte Corp., Wyandotte, Michigan, under the registered trademark “Tetronic”.
  • An analogous of series of surfactants, suitable for use in the present invention, is the poloxamer series which is a poly(oxyethylene) poly(oxypropylene) block polymers available under the trademark "Pluronic” (commercially available form BASF).
  • Amphoteric surfactants suitable for use in a composition according to the present invention include materials of the type are offered commercially under the trade name "Miranol.” Another useful class of amphoteric surfactants is exemplified by cocoamidopropyl betaine, commercially available from various sources.
  • the foregoing surfactants when employed with a buffer enhancer will generally be present in an amount from 0.01 to 5.0 percent (w/w), preferably 1.0 to 5.0 percent
  • the aqueous solutions of the present invention for treating contact lenses are also adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids which is equivalent to a 0.9 percent solution of sodium chloride or 2.5 percent of glycerol solution.
  • the solutions are made substantially isotonic with physiological saline used alone or in combination, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the lenses will lose their desirable optical parameters.
  • excess saline may result in the formation of a hypertonic solution which will cause stinging and eye irritation.
  • the pH of the present solutions should be maintained within the range of 5.0 to 8.0, more preferably about 6.0 to 8.0, most preferably about 6.5 to 7.8, suitable buffers may be added, such as boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na 2 HPO , NaH 2 PO 4 and KH 2 PO 4 ) and mixtures thereof.
  • suitable buffers such as boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na 2 HPO , NaH 2 PO 4 and KH 2 PO 4 ) and mixtures thereof.
  • Borate buffers are preferred, particularly for enhancing the efficacy of biguanides.
  • buffers will be used in amounts ranging from about 0.05 to 2.5 percent by weight, and preferably, from 0.1 to 1.5 percent.
  • the disinfecting/preserving solutions of this invention preferably contain a borate or mixed phosphate buffer, containing one or more of boric acid, sodium borate, potassium tetraborate, potassium metaborate or mixtures of the same.
  • buffering agents in some instances it may be desirable to include sequestering agents in the present solutions in order to bind metal ions which might otherwise react with the lens and/or protein deposits and collect on the lens.
  • Ethylene-diaminetetraacetic acid (EDTA) and its salts (disodium) are preferred examples. They are usually added in amounts ranging from about 0.01 to about 0.2 weight percent.
  • Other suitable sequestering agents include gluconic acid, citric acid, tartaric acid and their salts, e.g. sodium salts.
  • aqueous isotonic solutions of the bis(biguanides) of Formula (I) with optional other germicidal agents are especially useful for soft contact lenses, with or without further additives.
  • the solutions of the present invention may be formulated into specific contact lens care products, such as wetting solutions, soaking solutions, cleaning and conditioning solutions, as well as multi-purpose type lens care solutions, etc. and mixtures thereof.
  • Such additives make the solutions more acceptable to the user in terms of greater comfort.
  • the additives must be non-toxic and compatible with contact lenses.
  • water-soluble viscosity builders in the solutions , of the present invention. Because of their demulcent effect, viscosity builders have a tendency to enhance the lens wearer's comfort by means of a film on the lens surface cushioning impact against the eye. Included among the water-soluble viscosity builders are the cellulose polymers like hydroxyethyl or hydroxypropyl cellulose, carboxymethyl cellulose and the like. Such viscosity builders may be employed in amounts ranging from about 0.01 to about 4.0 weight percent or less.
  • the present solutions may also include optional demulcents.
  • the aqueous solutions according to the present invention can be effectively used in disinfecting contact lenses by any of the well recognized methods.
  • the lenses may be treated by the "cold" soaking method at room temperature for a period ranging from about 20 minutes to about 12 hours.
  • the lenses are then removed from the solution, rinsed with the same or a different solution, for example a preserved isotonic saline solution and then replaced on the eye.
  • contact-lens wearers are commonly required to digitally or manually rub the contact lenses (typically between a finger and palm or between fingers) during daily cleaning and/or disinfecting of contact lenses.
  • a method is provided in which rubbing is not required during treatment with the claimed specified solution, between removal from the eye and replacement of the lens following lens care.
  • a soft lens is disinfected or both disinfected and cleaned with a multipurpose solution or an effective multipurpose solution that is the only daily solution needed for treating the lens outside the eye.
  • the described solution is used to treat a contact lens without rubbing, by a method comprising:
  • step (a) may involve immersing the contact lens in the solution. Soaking may optionally comprise shaking or similarly agitating a container of the solution by manual means. Preferably, step (a) involves a period of soaking the contact lens in a container wherein the contact lens is completely immersed in the solution.
  • direct placement is herein meant that the solution is not diluted or rinsed off the lens with a different contact-lens solution prior to "insertion" or placement on the eye.
  • the method uses a no-rub multi-purpose or effective multi-purpose solution, wherein no other solution or product is required for daily cleaning of the lens, with the possible exception of an enzyme cleaner.
  • the solution may be used to treat a lens, without rubbing the lens, in a regimen comprising a soak period that is less than four hours, for example, where sufficient disinfection can be obtained within a period that is in the range of about 20 minutes to about 90 minutes, wherein the recommended minimum soaking period is a given time within the range of about 20 minutes to about 90 minutes.
  • the solution may be formulated to provide the necessary disinfection, without rubbing, by soaking the lens in the solution for a given period within the range of about 50 minutes to about 70 minutes, preferably about 60 minutes, corresponding to a minimum soaking period of about 50 to about 70 minutes, preferably a minimum soaking period of about 60 minutes.
  • the claimed solution is used to clean a frequent replacement lens (FRL) that is planned for replacement after not more than about three months of use in the eye, or that is planned for replacement after not more than about 30 days of use in the eye, or that is planned for replacement after not more than about two weeks in the eye.
  • the lens is made from a polymer comprising about 0.0 to 5 mole percent repeat units derived from methacrylic acid (MAA), 10 to 99 mole percent of repeat units derived from hydroxyethyl methacrylate, and about 0.5 to 5 mole percent of cross-linking repeat units.
  • Cross-linking repeat units may be derived, for example, from such monomers as ethyleneglycol dimethacrylate, divinylbenzene, and trimethylpropane trimethacrylate.
  • This Example illustrates the preparation of 1,6 bis(cyanoguanidino) hexane, used as a starting material for bis(biguanides) of the present invention.
  • sodium dicyanamide NaC N 3
  • 1 -butanol 1 -butanol
  • 23.60 g (0.204 mole) of 1,6-hexanediamine were added as well as 33.0 mL of cone.
  • aqueous hydrochloric acid (0.400 mole).
  • a milky white precipitate appeared immediately which was probably the amine hydrochloride.
  • the mixture was then refluxed for 3.5 hr.
  • the suspension was then cooled to room temperature and filtered.
  • EXAMPLE 2 This Example illustrates the preparation of alexidine for use in the present invention. Hexamethylene bis(cyanoguanido) in the amount of 1.003g (0.004498 moles) was placed into a flask. To this was added 1.474 mL (1.163g; 0.008996 moles) of 2- ethylhexylamine. Then, 0.74 mL (0.008996 moles) of concentrated HCl was added. The mixture was heated in a flask to boil away the H 2 O. After the H 2 O was gone, the temperature of the melt had risen to 195°C. The temperature was decreased to 150- 160°C and maintained for 1 hour. The material was cooled to room temperature. The solid can be dissolved in hot water and allowed to crystallize.
  • EXAMPLE 3 This Example illustrates the preparation of poly(hexamethylene biguanide), also referred to as PAPB or PHMB, for use in combination with bis(biguanides) in the present invention.
  • PAPB poly(hexamethylene biguanide)
  • PHMB poly(hexamethylene biguanide)
  • This Example illustrates the preparation of an aqueous contact-lens disinfectant solution according to the present invention.
  • the solution is prepared by gradually heating 80 percent of the water to 80°C while dissolving the disodium EDTA therein.
  • the boric acid and sodium borate are added to the heated solution of disodium EDTA and dissolved.
  • the sodium chloride is then added to the solution and dissolved, followed by the addition of surfactants.
  • the solution is sterilized by autoclaving to 120°C for 45 minute. After the solution is cooled to room temperature, the bis(biguanide) is added through a sterile filter, followed by the balance of distilled water.
  • the solution is packaged in sterilized plastic containers.
  • This Example illustrates the microbiocidal efficacy of solutions according to the present invention.
  • the antimicrobial efficacy of each of various compositions for the chemical disinfection of contact lenses was evaluated.
  • Microbial challenge inoculums were prepared using Pseudomonas aeruginosa (ATCC 9027), Staphylococcus aureus (ATCC 6538), Serratia marcescens (ATCC 13880), Candida albicans (ATCC 10231), and Fusarium solani (ATCC 36031).
  • test organisms were cultured on appropriate agar and the cultures were harvested using sterile DPBST (Dulbecco's Phosphate Buffered Saline plus 0.05% w/v polysorbate 80) or a suitable diluent and transferred to a suitable vessel. Spore suspensions were filtered through sterile glass wool to remove hyphal fragments. Serratia marcescens, as appropriate, was filtered (eg., through a 1.2 ⁇ filter) to clarify the suspension. After harvesting, the suspension was centrifuged at no more than 5000 x g for a maximum of 30 minutes at 20-25°C. The supernatant was poured off and resuspended in DPBST or other suitable diluent.
  • the suspension was centrifuged a second time, and resuspended in DPBST or other suitable diluent. All challenge bacterial and fungal cell suspensions were adjusted with DPBST or other suitable diluent to 1 x 10 7 -10 8 cfu/mL. The appropriate cell concentration may be estimated by measuring the turbidity of the suspension, for example using a spectrophotometer at a preselected wavelength, for example 490 nm. One tube was prepared containing a minimum of 10 mL of test solution per challenge organism.
  • Each tube of the solution to be tested was inoculated with a suspension of the test organism sufficient to provide a final count of 1.0 x 10 5 -10 6 cfu/mL, the volume of the inoculum not exceeding 1% of the sample volume. Dispersion of the inoculum was ensured by vortexing the sample for at least 15 seconds.
  • the inoculated product was stored at 10- 25°C. Aliquots in the amount of 1.0 mL were taken of the inoculated product for determination of viable counts after certain time periods of disinfection.
  • the time points for the bacteria were, for example, 1, 2, 3, and 4 hours when the proposed regimen soaking time was 4 hours. Yeast and mold were tested at an additional timepoint of > 16 hours (4 times the regimen time).
  • the suspension was mixed well by vortexing vigorously for at least 5 second.
  • the 1.0 mL aliquots removed at the specified time intervals were subjected to a suitable series of decimal dilutions in validated neutralizing media.
  • the suspensions were mixed vigorously and incubated for a suitable period of time to allow for neutralization of the microbial agent.
  • the viable count of organisms was determined in appropriate dilutions by preparation of triplicate plates of trypticase soy (TSA) agar for bacteria and Sabouraud dextrose agar (SDA) for mold and yeast.
  • TSA trypticase soy
  • SDA Sabouraud dextrose agar
  • the yeast was incubated at 20-30°C for 2-4 days and mold recovery plates at 20-25°C for 3-7 days. The average number of colony forming units was determined on countable plates. Countable plates refer to 30-300 cfu/plates for bacteria and yeast, and 8 to 80 cfu/plate for mold except when colonies are observed only for the 10° or 10 "1 dilution plates. The microbial reduction was then calculated at the specified time points.
  • inoculum controls were made by dispersing an identical aliquot of the inoculum into a suitable diluent, for example DPBST, using the same volume of diluent used to suspend the organism as listed above. Following inoculation in a validated neutralizing broth and incubation for an appropriate period of time, the inoculum control must be between 1.0 x 10 5 - 1.0 x 10 6 cfu/mL
  • the solutions were evaluated based on the performance requirement referred to as the "Stand-Alone Procedure for Disinfecting Products" (hereafter the "stand-alone test") and is based on the Disinfection Efficacy Testing for contact lens care products under the Draft Premarket Notification (510(k)) Guidance Document For Contact Lens Care Products dated April 1, 1996, prepared by the U.S. Food and Drug Administration, Division of Ophthalmic Devices. This performance requirement is comparable to current ISO standards for disinfection of contact lenses (revised 1995).
  • the stand-alone test challenges a disinfecting product with a standard inoculum of a representative range of microorganisms and establishes the extent of viability loss at pre-determined time intervals comparable with those during which the product may be used..
  • the primary criteria for a given disinfection period (corresponding to a potential minimum recommended disinfection period) is that the number of bacteria recovered per mL must be reduced by a mean value of not less than 3.0 logs within the given disinfection period.
  • the number of mold and yeast recovered per mL must be reduced by a mean value of not less than 1.0 log within the minimum recommended disinfection time with no increase at four times the minimum recommended disinfection time.
  • the secondary performance criteria exists which if passed qualifies the solution for the so-called "regimen test procedure" described in the FDA's Draft for Premarket Notification (510(k)) Guidance Document For Contact Lens Care Product, dated April 1, 1996 or similarly described in the ISO/CEN regimen test procedure.
  • the secondary performance criteria there must be a combined log reduction for the mean values of all three bacteria of not less than 5.0 logs within the recommended given disinfection period.
  • the minimum acceptable mean log reduction for any single bacterial type is 1.0 log. Stasis for the yeast and mold must be observed for the recommended disinfection period.
  • the regimen test challenges the proposed disinfection regimen (typically involving rubbing) with a standard inoculum of a representative range of microorganisms, in which test the inoculum is carried through the various stages of regimen by preliminary application to contact lenses.
  • Example 4 shows the antimicrobial efficacy of the solution of Example 4 according to the present invention using the testing procedures described in Example 5 above, but formulated at a concentration of 4.0 ppm alexidine and at time intervals of 15 minutes, 30 minutes, 45 minutes, and 60 minutes, which would represent 25%, 50%, 75% and 100% of a one hour minimum recommended disinfection time.
  • the solution had been aged for 19 months at 25°C. The results are shown in Table 3 below.
  • the alexidine solution formulated at 4.0 ppm is able to pass a stand-alone test (with no rub or rinse) at the 30 minute time point, 45 time point and the 60 minute time point. With respect to Staphylococcus aureus the 15 minute time point failed.
  • Example 4 shows the antimicrobial efficacy of a solution according to the present invention using the testing procedures described in Example 5 above. These tests were similar to Example 6 except with a different lot that had been aged for 18 months. The concentration of alexidine was formulated at 4.0 ppm and the time intervals were 15 minutes, 30 minutes, 45 minutes, and 60 minutes. The results are shown in Table 4 below.
  • This Example shows the antimicrobial efficacy of a solution according to the present invention using the testing procedures described in Example 5 above. For a final time, these tests were similar to Example 6 except with a different batch.
  • the concentration of alexidine was formulated at 4.0 ppm and the time intervals were 15 minutes, 30 minutes, 45 minutes, and 60 minutes, which would represent 25%, 50% and 100% of a one hour minimum recommended disinfection period.
  • the solution had been aged 19 months at 25°C. The results are shown in Table 5 below.
  • the alexidine solution passed the stand-alone test (without rubbing) at 30 minutes, 45 minutes, and 60 minutes, but did not pass the test at 15 minutes, since at 15 minutes the log reduction for Serratia marcescens was less than 3 logs and the number of the yeast Candida albicans was not reduced by at least 1 log.
  • Tables 3, 4, and 5 above show some variation due to the testing of different lots of the solutions described in Example 4 above, but that a 4.0 ppm alexidine solution would require at least about 30 minutes in order to pass a stand-alone procedure without rubbing.
  • This Example compares the antimicrobial efficacy of a solution according to the present invention (such as formulated in Example 4) compared to an analogous solution containing only PHMB as the germicide. Both solutions were borate buffered to enhance the efficacy of the biguanide.
  • the testing procedures used for evaluating the antimicrobial efficacy of disinfecting solutions was the same as in Example 5 above. The results are shown in Table 6 below.
  • the acceptance criteria was that the number of bacteria recovered per mL must be reduced by a factor of not less than 99.9% (3 logs) with the minimum disinfection period (which would be recommended with the product, in label, package, and/or package insert instructions), and the number of mold and yeast recovered per mL shall be reduced by a factor of not less than 90% (1 log) within the minimum recommended disinfection time, with no increase at four times the minimum recommended disinfection time.
  • the above results show that the 1.0 ppm PHMB did not pass the one hour stand-alone test, since the Fusarium solani, a mold, was not sufficiently reduced.
  • the 4.0 ppm alexidine solution according to the present invention passed the one hour stand-alone test, showing a reduction in the number of mold by 3.1 log after 1 hour.
  • PHMB is used in an amount of about 1.0 ppm in commercial solutions for disinfecting soft lenses. It has been found that increasing the level of PHMB to 3.0 ppm results in clinical findings that suggest PHMB may be less safe than desirable, for use with soft contact lens. In contrast, as shown in the next example, based on rabbit studies, it has been found that a 4.0 ppm solution of alexidine would be very safe for human use in disinfecting soft lenses.
  • This example demonstrates the ocular toxicology of alexidine in solutions such as described in Example 4 above, but at various concentrations of the bis(biguanide).
  • a series of formulations were prepared in which the amount of alexidine were, respectively 4 ppm (test 1), 6 ppm (test 2), 8 ppm (test 3), 10 ppm (test 4), 12 ppm (test 5), 15 ppm (test 6), 18 ppm (test 7) , 22 ppm (test 8), 27 ppm (test 9), 33 ppm (test 10), 40 ppm (test 11) and 50 ppm (test 12).
  • These test solutions of alexidine were used in soaking J&J SureVue® (etafilcon A) lenses (soft lenses) in 2.5 mL of solution for 1 week or more in order to reach maximal alexidine uptake.
  • EXAMPLE 11 This example illustrates the preparation of aqueous disinfecting solutions according to the present invention comprising a combination of alexidine and polyhexamtheylene biguanide (also referred to as PAPB or PHMB). The following components are used, in the indicated percent weight per total volume of the solution:
  • Poloxamine 1107** 1.0 Na 2 EDTA 0.11
  • the solution is prepared by gradually heating 80 percent of the water to 80°C while dissolving the disodium EDTA therein.
  • the boric acid and sodium borate are added to the heated solution of disodium EDTA and dissolved.
  • the sodium chloride is then added to the solution and dissolved, followed by the addition of surfactants.
  • the solution is sterilized by autoclaving to 120°C for 45 minute. After the solution is cooled to room temperature, the bis(biguanide) and the PAPB are added through a sterile filter, followed by the balance of distilled water.
  • the solution is packaged in sterilized plastic containers.
  • EXAMPLE 12 This Example illustrates the improved antimicrobial efficacy of a combination of alexidine with polyhexamtheylene biguanide (PAPB) in an aqueous disinfecting solution for contact lenses.
  • PAPB polyhexamtheylene biguanide
  • the testing procedures described in Example 5 above were followed to determine whether the primary performance criteria would be passed at time intervals of 5 minutes, 15 minutes, 30 minutes, and 4 hours.
  • the concentration of alexidine in this set of tests was formulated in amounts ranging from 0.0 to 4.0 ppm in combination with either 0.0 (control) or 0.8 ppm alexidine, the latter the amount of PAPB currently used in commercial multi-purpose solutions for soft contact lenses.
  • Table 8 The results are shown in Table 8 below.
  • This example illustrates the preparation of an aqueous disinfecting solution according to the present invention comprising a combination of alexidine and polyhexamtheylene biguanide (also referred to as PHMB).
  • PHMB polyhexamtheylene biguanide
  • the solution is prepared by gradually heating 80 percent of the water to 80°C while dissolving the disodium EDTA therein.
  • the boric acid and sodium borate are added to the heated solution of disodium EDTA and dissolved.
  • the sodium chloride is then added to the solution and dissolved, followed by the addition of the surfactant.
  • the solution is sterilized by autoclaving to 120°C for 45 minute. After the solution is cooled to room temperature, the alexidine bis(biguanide) and the PHMB are added through a sterile filter, followed by the balance of distilled water.
  • the solution is packaged in sterilized plastic containers.
  • This Example illustrates the microbiocidal efficacy of solutions according to the present invention.
  • the above testing procedures were used for evaluating the antimicrobial efficacy against C. albicans of disinfecting solutions such as prepared in Example 13, but which contain the bis(biguanide) alexidine at various concentrations extending from 1 ppm to 4 ppm and the biguanide polymer at various concentrations extending from 0.3 to 1.5 ppm.
  • the results are shown in Table 10 after a 5 minute soak, Table 11 after a 15 minute soak, Table 12 after a 30 minute soak, and Table 13 after a 45 minute soak.
  • Tables 14 to 17, corresponding respectively to Tables 10 to 13 compares the theoretical kill, based on the sum of individual disinfecting agents versus actual kill using the combination of disinfecting agents.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Detergent Compositions (AREA)
  • Eyeglasses (AREA)

Abstract

Cette invention concerne une solution désinfectante pour lentilles de contact qui ne présente pas de risques sur le plan ophtalmologique, et qui comprend un bis(guanide) correspondant à la formule (I) où R1 et R4 sont choisis indépendamment dans le groupe comprenant les éléments suivants: un alkyle ramifié ou non ramifié comportant de 4 à 12 atomes de carbone, un radical éther ou thioéther comportant de 4 à 12 atomes de carbone, ou un radical cycloalkyle ou cycloalkyl-alkyle comportant de 5 à 12 atomes de carbone. R2 et R3 sont indépendamment choisis dans le groupe comprenant les éléments suivants: hydrogène, alkyle comportant de 1 à 12 atomes de carbone, alcoxyalkyle comportant de 1 à 12 atomes de carbone, ou cycloalkyle ou cycloalkyl-alkyle comportant de 5 à 12 atomes de carbone. R6 et R7 sont quant à eux choisis dans le groupe comprenant hydrogène et un radical alkyle comportant de 1 à 6 atomes de carbone. A est choisi à partir d'un radical divalent qui comprend de 4 à 16 atomes de carbone et qui consiste en un alkyle, un alkyloxyalkyle ou un alkylsulfure divalents ou, encore, en un polyméthylène interrompu par un radical divalent cyclique. Dans un mode de réalisation, ces biguanides peuvent être combinés à un biguanide polymère afin d'obtenir une efficacité biocide additionnelle ou synergique. Cette invention concerne également un procédé amélioré de désinfection de lentilles de contact.
EP97948172A 1996-11-13 1997-11-04 Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact Withdrawn EP0942653A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3164696P 1996-11-13 1996-11-13
US31646P 1996-11-13
PCT/US1997/020087 WO1998020738A1 (fr) 1996-11-13 1997-11-04 Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact

Publications (1)

Publication Number Publication Date
EP0942653A1 true EP0942653A1 (fr) 1999-09-22

Family

ID=21860642

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97948172A Withdrawn EP0942653A1 (fr) 1996-11-13 1997-11-04 Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact

Country Status (7)

Country Link
EP (1) EP0942653A1 (fr)
JP (1) JP2001504246A (fr)
KR (1) KR20000053221A (fr)
AU (1) AU5429198A (fr)
BR (1) BR9713049A (fr)
CA (1) CA2269764A1 (fr)
WO (1) WO1998020738A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697820A (zh) * 2016-02-17 2018-10-23 株式会社实瞳 抗棘阿米巴接触镜用溶剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739900B2 (en) * 1996-11-13 2001-10-25 Bausch & Lomb Incorporated Disinfecting contact lenses with bis(biguanides) and polymeric biguanides
KR20010031987A (ko) * 1997-11-12 2001-04-16 스티븐 에이. 헬렁 폴리콰터니움 및 중합체 비구아니드에 의한 콘택트 렌즈의소독
ID25783A (id) * 1997-11-12 2000-11-02 Bausch & Lomb Pembasmian kumam pada lensa kontak dengan bis (guanida) dan biguanida polimerik
US6369112B1 (en) 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
US6309596B1 (en) * 1998-12-15 2001-10-30 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
EP1140805A1 (fr) 1998-12-18 2001-10-10 Alcon Laboratories, Inc. Amidopolybiguanides et utilisation de ceux-ci en tant qu'agents antimicrobiens
AU2195800A (en) 1998-12-18 2000-07-03 Alcon Laboratories, Inc. Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
US6634748B1 (en) * 2000-11-15 2003-10-21 Johnson & Johnson Vision Care, Inc. Methods of stabilizing silicone hydrogels against hydrolytic degradation
US20040204496A1 (en) * 2003-04-11 2004-10-14 Ammon Daniel M. Disinfecting solutions effective against bacterial endospores
US20060067981A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Contact lens with improved biocidal activity and related methods and materials
US7897553B2 (en) * 2006-10-23 2011-03-01 Bausch & Lomb Incorporated Biguanide composition with low terminal amine
IL190181A (en) 2008-03-16 2015-08-31 Altos Medical Llc Cleaning, sanitizing and sterilizing products
WO2014060755A1 (fr) 2012-10-17 2014-04-24 Arcis Biotechnology Holdings Limited Préparations nettoyantes, aseptisantes et stérilisantes
CN105010379B (zh) * 2014-04-30 2018-06-01 宁波润增医疗科技有限公司 杀菌剂及其应用
CN110121548A (zh) * 2017-01-03 2019-08-13 陈煌兴 支化聚合双胍化合物及其用途
CN110078913B (zh) * 2019-05-29 2021-08-24 湖南雪天精细化工股份有限公司 一种聚六亚甲基双胍盐酸盐的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8312663D0 (en) * 1983-05-09 1983-06-15 Ici Plc Bisbiguanide compounds
CA2009118C (fr) * 1989-02-21 1996-02-27 Mary F. Mowrey-Mckee Methode et compose pour nettoyer et desinfecter les verres de contact
US4891423A (en) * 1989-03-20 1990-01-02 Stockel Richard F Polymeric biguanides
KR100262055B1 (ko) * 1993-01-07 2001-11-22 카를 새쌔노 콘택트렌즈용액용방부제시스템

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9820738A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697820A (zh) * 2016-02-17 2018-10-23 株式会社实瞳 抗棘阿米巴接触镜用溶剂

Also Published As

Publication number Publication date
CA2269764A1 (fr) 1998-05-22
AU5429198A (en) 1998-06-03
WO1998020738A1 (fr) 1998-05-22
BR9713049A (pt) 2000-04-04
KR20000053221A (ko) 2000-08-25
JP2001504246A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
US5965088A (en) Method for providing rapid disinfection of contact lenses
AU737541B2 (en) Disinfecting contact lenses with polyquaterniums and polymeric biguanides
AU734700B2 (en) Treatment of contact lenses with aqueous solution comprising an alkali carbonate
US6143244A (en) Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant and a complementary phosphate-borate buffer system
EP1140224B1 (fr) Agent de nettoyage de lentilles de contact contenant du biguanide, du tyloxapol et une poloxamine
US6309596B1 (en) Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
WO1998020738A1 (fr) Compositions et procedes faisant appel a des bis(guanides) afin d'obtenir une meilleure activite antimicrobienne lors de la desinfection de lentilles de contact
EP0938344B1 (fr) Procede de decontamination rapide des lentilles de contact
WO1999024542A1 (fr) Desinfection de lentilles de contact au moyen de bis(biguanides) et de biguanides polymeres
AU739900B2 (en) Disinfecting contact lenses with bis(biguanides) and polymeric biguanides
MXPA00004564A (en) Disinfecting contact lenses with bis(biguanides) and polymeric biguanides
MXPA00004566A (en) Disinfecting contact lenses with polyquaterniums and polymeric biguanides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IE IT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARSCH, DAVID, A.

Inventor name: SIMPSON, LISA, C.

Inventor name: HEILER, DAVID, J.

Inventor name: SPOONER, SUSAN, P.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010531

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1024837

Country of ref document: HK